Építés alatt – nem éles oldal
Belépés
Befejeződött1. fázis

Cannabinoids for Pain Management and Neuroprotection From Concussion

A legfontosabb adatok

Ki végzi
University of Regina
Hol
Kanada2 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Befejeződött
Fázis
1. fázis
Résztvevők
34 fő vett részt
Kezdés
2024. febr. 15.
Befejezés
2024. nov. 30.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • Cannabis/Hemp Isolate Extract
A regiszteradat frissítve
2026. május 6.

Ki vehet részt

Életkor
18 év – 35 év
Nem
Csak férfiak
Egészséges önkéntesek
Részt vehetnek

A regiszter feltételei, szó szerint

Mind a 16 feltétel megnézéseKevesebb

Ki vehet részt

  • Healthy male adults between 18-35 years of age that compete in contact sport athletics
  • No known cerebrovascular or cardiovascular complications
  • Not habitual recreational users of cannabis (i.e., <1 day/week) or tobacco users
  • Agree not to consume any other cannabis or tobacco products while enrolled in the study
  • Agree to list any prescription medications being taken
  • Ability to maintain commitment to all proposed biopsychological and health questionnaires, and neuro-physiological, physiological, perceptual-cognitive, and functional motor skills laboratory tests

Ki nem vehet részt

  • Use of cannabis-based therapy within 2 months (participants who have previously used a cannabis based therapy may be included if they have a 2 month period without use of cannabis based therapy prior to enrolment in the study)
  • Initiation or dosage change of oral or injected steroids within past 3 months
  • Medically supervised for anxiety, depression, or other neurological conditions
  • Allergy or known intolerance to any of the compounds within the study preparation
  • Inability to attend assessments on a regular basis at the pre-determined times, or failure to take drug on a daily basis
  • Clinically significant cardiac, renal or hepatic disease (as assessed by the site investigator)
  • Female
  • Requirement to travel to the USA during study period; USA laws do not permit cross border with cannabis products
  • Any level of cannabis in blood samples when sampled at the commencement of the study
  • Concussion

Hol van ez a vizsgálat?

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

The goal of this open-label, placebo-controlled, dosage escalation study is to learn about the safety of a Cannabis/Hemp Isolate Extract in normal healthy adults engaged in elite contact sport competition.

A teljes eredeti leírásKevesebb

The main question it aims to answer is:

• Are cannabis/hemp-based products with high CBD safe, well-tolerated and without adverse physiological and psychological dysfunction, when administered on a daily basis?

Participants will:

* be given CBD and a placebo. The placebo will be taken for 2 weeks prior to starting the CBD. Participants will start on a low dose of CBD, beginning at 5 mg CBD/kg body mass, which will be increased by 5 mg/kg every 2-weeks until 30 mg CBD/kg body mass is taken; * have blood samples taken to analyse how much CBD is used in the body and for how long it lasts in the body (pharmacokinetics and pharmacodynamics); * have saliva samples collected for genetic analysis; * undergo testing sessions, which will include psychological and health questionnaires, equipment to record signals from the brain and heart, and safety laboratory tests.

A vizsgálat csoportja

  • Dose EscalationA vizsgált kezelés

    When participants start the CBD, they will be started on a low dose of CBD, beginning at 5 mg CBD/kg body mass, and then increased by 5 mg/kg every 2-weeks until 30 mg CBD/kg body mass is taken.

    Kezelés: Cannabis/Hemp Isolate Extract

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Naturally Produced Cannabinoids for Pain Management and Neuroprotection From Concussion During Participation in Contact Sports: Dose Escalation
Publikációk
A regiszteradat frissítve
2026. május 6.